What Key Growth Drivers Are Shaping The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast Toward $3.09 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Today And What Is Its Future Size?
The market size for chronic inflammatory demyelinating polyneuropathy (cidp) has seen robust growth in the past few years. This growth trend is projected to continue, with the market set to expand from $2.1 billion in 2024 to $2.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.1%. The notable growth in the past years can be linked to factors like a growing elder population, innovations in treatment methods, heightened awareness and earlier diagnosis practices, advancements in immunology and research in autoimmune diseases, and an increased incidence rate of autoimmune diseases.
The market size for chronic inflammatory demyelinating polyneuropathy (cidp) is projected to strongly surge in the following years, swelling to $3.09 billion by 2029 based on a compound annual growth rate (CAGR) of 7.9%. The upward trajectory during the forecast period is anticipated due to an elderly worldwide population, increased attention on uncommon illnesses and autoimmune conditions, enhanced access to medical care, advocacy, and awareness campaigns by patients, as well as improved healthcare frameworks. The forecast period is set to witness an escalating prevalence of chronic inflammatory demyelinating polyneuropathy, advances in treatment choices, an uptick in research and developmental initiatives, the rise of biosimilar therapies, and the advent of personalized healthcare strategies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Which Demand Drivers Are Strengthening The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is set to grow, propelled by the rising healthcare expenditure. The increase in healthcare spending is attributed to more investments in medical facilities, a burgeoning demand for sophisticated treatments, wider insurance coverage, and governmental interventions to boost healthcare accessibility. Greater healthcare expenditure facilitates earlier diagnosis, better CIDP management, and access to advanced therapies, thus enhancing patients’ health outcomes and the quality of life. For instance, the UK-based Office for National Statistics reported in May 2024 that the total healthcare expenditure had seen a nominal increase of 5.6% from 2022 to 2023. This is a marked leap compared to the 2022 growth of 0.9%. Hence, it’s clear that the chronic inflammatory demyelinating polyneuropathy (CIDP) market’s growth is driven by the surge in healthcare expenditure.
Which Segment Accounts For The Largest Share In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The chronic inflammatory demyelinating polyneuropathy (cidp)market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin; Corticosteroids; Plasmapheresis; Physiotherapy; Other Treatments
2) By Route Of Administration: Intravenous; Oral; Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing; Nerve Conduction; Electromyography (EMG); Spinal Fluid Analysis; Other Diagnosis
4) By Distribution Channel: Hospitals; Pharmacies; Online Pharmacies; Specialty Clinics
5) By End User: Hospitals; Research Institutions; Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy; High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids; Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis; Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises; Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents; Monoclonal Antibodies
Which Long-Term Trends Will Play A Crucial Role In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Key players in the chronic inflammatory demyelinating polyneuropathy (CIDP) sphere are concentrating on advancements such as intravenous immunoglobulin (IVIG) to boost treatment effectiveness, improve patient results, and offer more precise and effective immune regulation for managing CIDP. Intravenous immunoglobulin (IVIG) is a form of treatment where concentrated antibodies from healthy donors are infused to alter the immune system and decrease inflammation in autoimmune conditions. For example, in January 2024, Japan’s Takeda Pharmaceutical Company Limited announced that the FDA had approved GAMMAGARD LIQUID as an IVIG therapy for adult CIDP patients. This endorsement permits its application as an induction therapy, commencing with an initial dose, followed by maintenance doses to aid long-term disease control and enhance neuromuscular function.
Which Companies Hold A Competitive Edge In The 1383 Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In The Coming Years?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2025, By The Business Research Company
Chronic Disease Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report
Chronic Lower Back Pain Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report
Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
